Aquestive Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGAquestive Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Earnings contraction of 37% provides fundamental context to the price action. Investors should exercise caution due to high volatility (88% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.17 | +1.37% | ABOVE |
| 50 SMA | $4.14 | +2.13% | ABOVE |
| 100 SMA | $4.36 | -3.05% | BELOW |
| 150 SMA | $5.00 | -15.46% | BELOW |
| 200 SMA | $4.86 | -12.97% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AQST in an uptrend right now?
AQST has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is AQST overbought or oversold?
AQST's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is AQST outperforming the market?
AQST has a Relative Strength (RS) Rating of 31 out of 99. AQST is currently lagging the broader market.
Where is AQST in its 52-week range?
AQST is trading at $4.23, which is 56% of its 52-week high ($7.55) and 39% above its 52-week low ($2.12).
How volatile is AQST?
AQST has a Beta of 1.30 and 52-week volatility of 88%. It's more volatile than the S&P 500 - expect bigger swings.